” In light of the solid performance in the first half of 2023 combined with the strong demand for our GLP-1-based diabetes care products, we have adjusted upwards our outlook for both sales and profit growth for 2023. Lars Fruergaard Jørgensen, president & CEO 2/2023 • SHARE Magazine 5
Download PDF file